Objective: Study the relation between quality of life (QoL) and various clinical, therapeutic and sociodemographic variables in treated hypertensive patients.
Material And Methods: A prospective study was carried out in 92 primary care centres in Spain. A total of 269 hypertensive patients were selected and 106 healthy normotensive individuals were included as controls. At the time of inclusion a wide range of clinical variables was documented. QoL was assessed at baseline and 1 month after the intensification of antihypertensive therapy, using a self-administered, specific hypertension, 56-item questionnaire in addition to the generic EuroQoL-5D.
Results: QoL was poorer among the hypertensive subjects than among the normotensive individuals, even adjusting for the differences observed between the groups (age, sex, education and working status). The same was found with the EuroQol-5D. In the hypertensive subjects, after applying a multiple regression equation, only four variables significantly retained their negative impact on QoL: sex (female), greater organ damage and higher heart rate and weight. After the intensification of antihypertensive therapy with irbesartan, QoL improved significantly. Neither the presence of side-effects during the month of follow-up, nor the degree of BP reduction showed a significant impact on QoL, although the latter came close to statistical significance.
Conclusions: Hypertensive patients have significantly poorer QoL than normotensive subjects, even with adjustment for differences. In hypertensives, QoL is affected by some clinical variables that might help us to identify those with worse QoL. Intensification of antihypertensive therapy produced a positive impact on QoL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00004872-200110000-00028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of insulin initiation with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A real-world claims database study in Japan.
Diabetes Obes Metab
January 2025
Medical Affairs, Astellas Pharma Inc, Tokyo, Japan.
Aims: Insulin therapy is a cornerstone in type 2 diabetes mellitus (T2DM) management, but its use is associated with several barriers, including hypoglycaemia, fear of injections and high costs. We compared the risk of insulin initiation and other treatment intensification between patients with T2DM newly treated with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) versus those newly treated with a dipeptidyl peptidase-4 inhibitor (DPP4i).
Materials And Methods: This Japanese retrospective cohort study was conducted between 1 January 2015 and 31 March 2023 using the JMDC Claims Database.
Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials.
Obesity (Silver Spring)
January 2025
Novo Nordisk Inc., Plainsboro, New Jersey, USA.
Objective: The objective of this study was to assess antihypertensive and lipid-lowering treatment changes in participants receiving semaglutide 2.4 mg versus placebo across pooled populations from five Semaglutide Treatment Effect in People with Obesity (STEP) trials.
Methods: Efficacy and safety of semaglutide 2.
Insight into the interaction of serum albumin with antihypertensive peptide Val-Ala-Pro from bovine casein hydrolysate based on the biolayer interferometry, multi-spectroscopic analysis and computational evaluation.
Spectrochim Acta A Mol Biomol Spectrosc
March 2025
Guangxi Key Laboratory of Petrochemical Resource Processing and Process Intensification Technology, School of Chemistry and Chemical Engineering, Guangxi University, Nanning 530004, People's Republic of China; Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, People's Republic of China. Electronic address:
Article Synopsis
- Food-derived angiotensin-converting enzyme inhibitory peptide (ACEIP), specifically Val-Ala-Pro (VAP), shows potential in managing hypertension by interacting with the model protein bovine serum albumin (BSA).
- Various analytical techniques like multi-spectroscopy, biolayer interferometry, and molecular simulations showed that VAP binds to BSA, leading to structural changes in BSA, such as decreased hydrophobicity and unfolding.
- The binding process is primarily driven by entropy, with VAP binding to site II of BSA through multiple forces including hydrogen bonding and hydrophobic interactions, highlighting the importance of ACEIPs in therapeutic applications.
Therapeutic inertia and contributing factors among ambulatory patients with hypertension.
BMC Cardiovasc Disord
September 2024
Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Mekelle University, Ethiopia, Mekelle, Tigray.
Article Synopsis
- Therapeutic inertia is the reluctance of healthcare providers to escalate treatment for patients with poorly controlled hypertension, even when guidelines suggest otherwise, and it has become a key reason for inadequate hypertension management.
- This study aimed to explore the prevalence and causes of therapeutic inertia specifically among ambulatory patients with hypertension at a cardiac clinic in northern Ethiopia, involving 282 participants tracked over six months.
- The findings revealed that 72% of participants with uncontrolled hypertension experienced therapeutic inertia, leading to recommendations for increased medication dose or the introduction of additional drugs to improve treatment outcomes.
Aims/hypothesis: Metabolic abnormalities such as central obesity, insulin resistance, dyslipidaemia and hypertension, often referred to as 'the metabolic syndrome' (or 'combined metabolic abnormalities'), are increasingly being identified in people living with type 1 diabetes, accelerating the risk for CVD. As a result, in recent years, treatment in people living with type 1 diabetes has shifted to improving overall metabolic health rather than glucose control alone. In Belgium, diabetes care for people living with type 1 diabetes is centrally organised.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!